A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)

A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK1006.

This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of MK1006

Inclusion Criteria:

• Participant is between 18 and 55 years of age. Participants up to 65 years of age may be enrolled in Panels B and C
• Female participants must be postmenopausal or otherwise unable to have children
• Participant has a body mass index (BMI) less than or equal to 42 kg/m^2 at the screening visit
• Participant has type 2 diabetes and is being treated with either diet and exercise or a single oral anti-hyperglycemic medication. For Panels B and C, participant may be treated with combination oral anti-hyperglycemic medications
• Participant is willing to follow the American Heart Association (AHA) diet and exercise program throughout the study
• Participant is a nonsmoker or has not used nicotine-containing products for 6 months prior to study start

Exclusion Criteria:

• Participant has a history of stroke, seizures, or other neurological disorders
• Participant has a recent history of eye infection or other inflammatory eye conditions
• Participant has glaucoma or is blind
• Participant has had eye surgery within 6 months of study start (Lasik is permitted)
• Participant has type 1 diabetes
• Participant cannot stop taking any of their current prescription or non-prescription medications during the study
• Participant consumes more than 3 alcoholic beverages per day
• Participant consumes more than 6 caffeinated beverages per day
• Participant has had major surgery or has donated blood within 4 weeks of study start
• Participant has multiple and/or severe allergies to drugs or food